Drugs, Brain, and Behavior
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’S Disease
life Review The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease Gianfranco Natale 1,2,* , Larisa Ryskalin 1 , Gabriele Morucci 1 , Gloria Lazzeri 1, Alessandro Frati 3,4 and Francesco Fornai 1,4 1 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy; [email protected] (L.R.); [email protected] (G.M.); [email protected] (G.L.); [email protected] (F.F.) 2 Museum of Human Anatomy “Filippo Civinini”, University of Pisa, 56126 Pisa, Italy 3 Neurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, 00135 Rome, Italy; [email protected] 4 Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, 86077 Pozzilli, Italy * Correspondence: [email protected] Abstract: The gastrointestinal (GI) tract is provided with a peculiar nervous network, known as the enteric nervous system (ENS), which is dedicated to the fine control of digestive functions. This forms a complex network, which includes several types of neurons, as well as glial cells. Despite extensive studies, a comprehensive classification of these neurons is still lacking. The complexity of ENS is magnified by a multiple control of the central nervous system, and bidirectional communication between various central nervous areas and the gut occurs. This lends substance to the complexity of the microbiota–gut–brain axis, which represents the network governing homeostasis through nervous, endocrine, immune, and metabolic pathways. The present manuscript is dedicated to Citation: Natale, G.; Ryskalin, L.; identifying various neuronal cytotypes belonging to ENS in baseline conditions. -
Concurrent Alcohol and Tobacco Dependence
Concurrent Alcohol and Tobacco Dependence Mechanisms and Treatment David J. Drobes, Ph.D. People who drink alcohol often also smoke and vice versa. Several mechanisms may contribute to concurrent alcohol and tobacco use. These mechanisms include genes that are involved in regulating certain brain chemical systems; neurobiological mechanisms, such as cross-tolerance and cross-sensitization to both drugs; conditioning mechanisms, in which cravings for alcohol or nicotine are elicited by certain environmental cues; and psychosocial factors (e.g., personality characteristics and coexisting psychiatric disorders). Treatment outcomes for patients addicted to both alcohol and nicotine are generally worse than for people addicted to only one drug, and many treatment providers do not promote smoking cessation during alcoholism treatment. Recent findings suggest, however, that concurrent treatment for both addictions may improve treatment outcomes. KEY WORDS: comorbidity; AODD (alcohol and other drug dependence); alcoholic beverage; tobacco in any form; nicotine; smoking; genetic linkage; cross-tolerance; AOD (alcohol and other drug) sensitivity; neurotransmitters; brain reward pathway; cue reactivity; social AODU (AOD use); cessation of AODU; treatment outcome; combined modality therapy; literature review lcohol consumption and tobacco ers who are dependent on nicotine Department of Health and Human use are closely linked behaviors. have a 2.7 times greater risk of becoming Services 1989). The concurrent use of A Thus, not only are people who alcohol dependent than nonsmokers both drugs by pregnant women can drink alcohol more likely to smoke (and (e.g., Breslau 1995). Finally, although also result in more severe prenatal dam- vice versa) but also people who drink the smoking rate in the general popula age and neurocognitive deficits in their larger amounts of alcohol tend to smoke tion has gradually declined over the offspring than use of either drug alone more cigarettes. -
Medications to Treat Opioid Use Disorder Research Report
Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States. -
Understanding Addiction, Helping Clients and Colleagues
ALABAMA LAWYER ASSISTANCE PROGRAM Understanding Addiction, Helping Clients and Colleagues By Jeanne Marie Leslie rugs change the brain–they according to the American Bar change its structure and how it Association, is 15 to 18 percent.3 D works.1 Many of these changes Lawyers rank high in the incidences of are responsible for the behaviors we see depression compared to other professions in individuals addicted to drugs. and a disproportionate number of Neuroscience has made significant lawyers commit suicide;4 in Alabama advances in our ability to identify and there are about a dozen lawyer suicides understand the mechanisms involved in every year. And these are only the ones the addicted brain. These advancements about which we know. Many lawyers, clearly confirm what many in the addic- including some you know, may be strug- tion medicine field have known for some gling with an addiction or mental health time: the obsession and compulsion to problem when help is readily available use drugs in the addicted brain is instinc- through ALAP. tual and paramount to survival.2 Ignorance and stigma have contributed Addiction Facts to the confusion, moral judgments and Dr. Nora D. Volkow, director of the poor understanding of this destructive National Institute of Drug Abuse and often fatal disease. Our courts are (NIDA), explains how the neuro-chemi- overwhelmed by the behaviors, criminal cal mechanisms of drug abuse catalyze and civil, associated with addiction. and accelerate the onset addiction: Therefore, understanding addiction is “Recognizing drug addiction as a chron- essential for lawyers. Lawyers are in ic, relapsing disease characterized by com- unique positions to initiate change, to pulsive drug seeking and use is critical to advocate for medical treatment over tra- being able to identify and help those who ditional sanctions and to refer individuals have it. -
Oxytocin Effects in Mothers and Infants During Breastfeeding
© 2013 SNL All rights reserved REVIEW Oxytocin effects in mothers and infants during breastfeeding Oxytocin integrates the function of several body systems and exerts many effects in mothers and infants during breastfeeding. This article explains the pathways of oxytocin release and reviews how oxytocin can affect behaviour due to its parallel release into the blood circulation and the brain. Oxytocin levels are higher in the infant than in the mother and these levels are affected by mode of birth. The importance of skin-to-skin contact and its association with breastfeeding and mother-infant bonding is discussed. Kerstin Uvnäs Moberg Oxytocin – a system activator increased function of inhibitory alpha-2 3 MD, PhD xytocin, a small peptide of just nine adrenoceptors . Professor of Physiology amino acids, is normally associated The regulation of the release of oxytocin Swedish University of Agriculture O with labour and the milk ejection reflex. is complex and can be affected by different [email protected] However, oxytocin is not only a hormone types of sensory inputs, by hormones such Danielle K. Prime but also a neurotransmitter and a as oestrogen and even by the oxytocin 1,2 molecule itself. This article will focus on PhD paracrine substance in the brain . During Breastfeeding Research Associate breastfeeding it is released into the brain of four major sensory input nervous Medela AG, Baar, Switzerland both mother and infant where it induces a pathways (FIGURES 2 and 3) activated by: great variety of functional responses. 1. Sucking of the mother’s nipple, in which Through three different release pathways the sensory nerves originate in the (FIGURE 1), oxytocin functions rather like a breast. -
ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
The ASAM NATIONAL The ASAM National Practice Guideline 2020 Focused Update Guideline 2020 Focused National Practice The ASAM PRACTICE GUIDELINE For the Treatment of Opioid Use Disorder 2020 Focused Update Adopted by the ASAM Board of Directors December 18, 2019. © Copyright 2020. American Society of Addiction Medicine, Inc. All rights reserved. Permission to make digital or hard copies of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for commercial, advertising or promotional purposes, and that copies bear this notice and the full citation on the fi rst page. Republication, systematic reproduction, posting in electronic form on servers, redistribution to lists, or other uses of this material, require prior specifi c written permission or license from the Society. American Society of Addiction Medicine 11400 Rockville Pike, Suite 200 Rockville, MD 20852 Phone: (301) 656-3920 Fax (301) 656-3815 E-mail: [email protected] www.asam.org CLINICAL PRACTICE GUIDELINE The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update 2020 Focused Update Guideline Committee members Kyle Kampman, MD, Chair (alpha order): Daniel Langleben, MD Chinazo Cunningham, MD, MS, FASAM Ben Nordstrom, MD, PhD Mark J. Edlund, MD, PhD David Oslin, MD Marc Fishman, MD, DFASAM George Woody, MD Adam J. Gordon, MD, MPH, FACP, DFASAM Tricia Wright, MD, MS Hendre´e E. Jones, PhD Stephen Wyatt, DO Kyle M. Kampman, MD, FASAM, Chair 2015 ASAM Quality Improvement Council (alpha order): Daniel Langleben, MD John Femino, MD, FASAM Marjorie Meyer, MD Margaret Jarvis, MD, FASAM, Chair Sandra Springer, MD, FASAM Margaret Kotz, DO, FASAM George Woody, MD Sandrine Pirard, MD, MPH, PhD Tricia E. -
Neurotransmitter Actions
Central University of South Bihar Panchanpur, Gaya, India E-Learning Resources Department of Biotechnology NB: These materials are taken/borrowed/modified/compiled from various resources like research articles and freely available internet websites, and are meant to be used solely for the teaching purpose in a public university, and for serving the needs of specified educational programmes. Dr. Jawaid Ahsan Assistant Professor Department of Biotechnology Central University of South Bihar (CUSB) Course Code: MSBTN2003E04 Course Name: Neuroscience Neurotransmitter Actions • Excitatory Action: – A neurotransmitter that puts a neuron closer to an action potential (facilitation) or causes an action potential • Inhibitory Action: – A neurotransmitter that moves a neuron further away from an action potential • Response of neuron: – Responds according to the sum of all the neurotransmitters received at one time Neurotransmitters • Acetylcholine • Monoamines – modified amino acids • Amino acids • Neuropeptides- short chains of amino acids • Depression: – Caused by the imbalances of neurotransmitters • Many drugs imitate neurotransmitters – Ex: Prozac, zoloft, alcohol, drugs, tobacco Release of Neurotransmitters • When an action potential reaches the end of an axon, Ca+ channels in the neuron open • Causes Ca+ to rush in – Cause the synaptic vesicles to fuse with the cell membrane – Release the neurotransmitters into the synaptic cleft • After binding, neurotransmitters will either: – Be destroyed in the synaptic cleft OR – Taken back in to surrounding neurons (reuptake) Excitable cells: Definition: Refers to the ability of some cells to be electrically excited resulting in the generation of action potentials. Neurons, muscle cells (skeletal, cardiac, and smooth), and some endocrine cells (e.g., insulin- releasing pancreatic β cells) are excitable cells. -
Amphetamines Help People Struggling with Amphetamine Addiction
Reducing Harm & Finding Help, Continued detox facilities, and addiction treatment programs can help with withdrawal. Amphetamine addiction can be treated in a residential setting (often called “rehab”) or in an outpatient setting (when the patient lives at home, but goes to treatment appointments 1-7 times per week). Effective types of counseling for benzodiazepine addiction include cognitive behavioral therapy, motivational interviewing, and twelve- step facilitation. There are also recovery support groups and online forums that can Amphetamines help people struggling with amphetamine addiction. Narcotics Anonymous, Alcoholics Anonymous, and groups like SMART Recovery or LifeRing are all available to support people with Information about amphetamine addiction. Recovery apps specific to amphetamine addiction can be downloaded to your smart phone that Your Health provide lists of recovery support meetings, reading material, tools like sobriety counters, and more. © 2016 Institute for Research, Education and Training in Addictions Amphetamines – Amphetamines & who inject amphetamines and/or share equipment can develop injection site What Are They? My Health, Continued infections, damage to their veins, Hepatitis B & C, HIV, and blood clots. Amphetamines are a category of drug that decisions. For some people, amphetamine include prescription medications (like intoxication can create or worsen mental Adderall), methamphetamine (often illness symptoms like anxiety, paranoia, and shortened to “meth”), and MDMA (often hallucinations. called “ecstasy” or “Molly”). Although these drugs are not identical, they are all included Unknown drugs: Because some amphetamines in the category of amphetamines. are illegal, they carry additional risks. Users of methamphetamine and MDMA cannot be Amphetamines are stimulants. They can sure of the drug’s contents or dose. -
Molecular Mechanisms of Addiction
Molecular Mechanisms of Addiction Eric J. Nestler Nash Family Professor The Friedman Brain Institute Medical Model of Addiction • Pathophysiology - To identify changes that drugs produce in a vulnerable brain to cause addiction. • Individual Risk - To identify specific genes and non-genetic factors that determine an individual’s risk for (or resistance to) addiction. - About 50% of the risk for addiction is genetic. Only through an improved understanding of the biology of addiction will it be possible to develop better treatments and eventually cures and preventive measures. Scope of Drug Addiction • 25% of the U.S. population has a diagnosis of drug abuse or addiction. • 50% of U.S. high school graduates have tried an illegal drug; use of alcohol and tobacco is more common. • >$400 billion incurred annually in the U.S. by addiction: - Loss of life and productivity - Medical consequences (e.g., AIDS, lung cancer, cirrhosis) - Crime and law enforcement Diverse Chemical Substances Cause Addiction • Opiates (morphine, heroin, oxycontin, vicodin) • Cocaine • Amphetamine and like drugs (methamphetamine, methylphenidate) • MDMA (ecstasy) • PCP (phencyclidine or angel dust; also ketamine) • Marijuana (cannabinoids) • Tobacco (nicotine) • Alcohol (ethanol) • Sedative/hypnotics (barbiturates, benzodiazepines) Chemical Structures of Some Drugs of Abuse Cocaine Morphine Ethanol Nicotine ∆9-tetrahydrocannabinol Drugs of Abuse Use of % of US population as weekly users 100 25 50 75 0 Definition of Drug Addiction • Loss of control over drug use. • Compulsive drug seeking and drug taking despite horrendous adverse consequences. • Increased risk for relapse despite years of abstinence. Definition of Drug Addiction • Tolerance – reduced drug effect after repeated use. • Sensitization – increased drug effect after repeated use. -
Everything You Wanted to Know but May Have Been Afraid to Ask
Wellness Tip Sheet Maryland State Bar Association’s Lawyer Assistance Program Everything you wanted to know but may have been afraid to ask What is Sexual Addiction? According to Dr. Founder of the International Institute for Trauma and Addiction Professionals (IITAP), sexual addiction is defined as any sexually related compulsive behavior which interferes with normal living and causes severe stress on family, friends, loved ones, or one’s work environment. Sexual addiction is sometimes referred to as sexual dependency or sexual compulsivity. By any name it is a compulsive behavior that completely dominates the addict’s life. Sexual addicts make sex a priority, making it more important than family, friends and work. Sex becomes the organizing principle of addicts’ lives. They are willing to sacrifice what they cherish most in order to preserve and continue their unhealthy behavior. Background Information: • It is estimated that 3 to 6% of the US population suffer from sexual addiction. That’s about 17 to 37 million people • Although it has traditionally been considered a middle aged male dominant addiction, females now represent more than 20% of the affected population. • Sex addiction does not discriminate. It crosses all educational, socioeconomic, racial and sexual-orientation lines, but one commonality among addicts is a sense of shame. • There has been progress in the medical field which includes sexual addiction being diagnosed as a disorder and having treatment options available. • In the past ten years treatment options have gone from fewer than 100 therapists to over 1,500, with treatment centers specializing in sexual addiction. What Causes Sexual Addiction? Sexual addiction, just like any addiction, is very complex. -
Oxytocinergic-System-A-Proposal.Pdf
Opinion Article iMedPub Journals ACTA PSYCHOPATHOLOGICA 2018 www.imedpub.com ISSN 2469-6676 Vol.4 No.3:14 DOI: 10.4172/2469-6676.100170 Oxytocinergic System: A Proposal João Paulo Correia Lima* and Avelino Luiz Rodrigues Received: April 17, 2018; Accepted: May 07, 2018; Published: May 18, 2018 Department of Clinical Psychology and Nucleus of Neuroscience and Behavior, Institute of Psychology, University of Sao Introduction Paulo, Brazil Since 1910, when Ott and Scott [1] published their discovers about the oxytocin participation in milk ejection, the comprehension *Corresponding author: about function and role of oxytocin in several physiological João Paulo Correia Lima functions didn’t stop enlarging and growing. In birth, through his action over uterus contractions, in uterus contractions in [email protected] women’s orgasm and men’s erection [2,3], for instance. However, this approach always considers its peripheral effects. After this, Psychologist for Neuroscience and Behavior, some oxytocin effects had been reported to have actions over Institute of Psychology, University of Sao behavioural traits, like we can see in publishings of Pedersen and Paulo, Brazil. Prange [4] and Winslow and co-workers [5], reporting the oxytocin actions over, respectively, maternal behaviour and pair bonding. Tel: +55-11-32852420; +55-11-983439754 Since then, the increasing data about the oxytocin’s function in behaviour and its central action can’t be ignored. In this short proposal, we’ll consider the opportunity or utility of thinking Citation about oxytocin as a system, instead of a single neurotransmitter. : Lima JPC, Rodrigues AL (2018) Oxytocinergic System: A Proposal. Acta Neurotransmitter or Hormone: Central Psychopathol Vol.4 No.3:14 and Peripheral Actions of Oxytocin Once a molecule could have his function defined through the way death, passive avoidance). -
Randomized Controlled Trial of Dexamphetamine Maintenance for the Treatment of Methamphetamine
RESEARCH REPORT doi:10.1111/j.1360-0443.2009.02717.x Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependenceadd_2717 146..154 Marie Longo1, Wendy Wickes1, Matthew Smout1, Sonia Harrison1, Sharon Cahill1 & Jason M. White1,2 Pharmacotherapies Research Unit, Drug and Alcohol Services South Australia, Norwood, South Australia, Australia1 and Discipline of Pharmacology, University of Adelaide, Adelaide, South Australia, Australia2 ABSTRACT Aim To investigate the safety and efficacy of once-daily supervised oral administration of sustained-release dexam- phetamine in people dependent on methamphetamine. Design Randomized, double-blind, placebo-controlled trial. Participants Forty-nine methamphetamine-dependent drug users from Drug and Alcohol Services South Australia (DASSA) clinics. Intervention Participants were assigned randomly to receive up to 110 mg/day sustained- release dexamphetamine (n = 23) or placebo (n = 26) for a maximum of 12 weeks, with gradual reduction of the study medication over an additional 4 weeks. Medication was taken daily under pharmacist supervision. Measurements Primary outcome measures included treatment retention, measures of methamphetamine consump- tion (self-report and hair analysis), degree of methamphetamine dependence and severity of methamphetamine withdrawal. Hair samples were analysed for methamphetamine using liquid chromatography-mass spectrometry. Findings Treatment retention was significantly different between groups, with those who received dexamphetamine remaining in treatment for an average of 86.3 days compared with 48.6 days for those receiving placebo (P = 0.014). There were significant reductions in self-reported methamphetamine use between baseline and follow-up within each group (P < 0.0001), with a trend to a greater reduction among the dexamphetamine group (P = 0.086).